Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics

E-ISSN： 1875-6190|13|5|616-635

ISSN： 1570-159X

Source： Current Neuropharmacology, Vol.13, Iss.5, 2015-09, pp. : 616-635

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Olanzapine/Fluoxetine: A Review of its Use in Patients With Treatment-Resistant Major Depressive Disorder

By Croxtall Jamie D. Scott Lesley J.

CNS Drugs, Vol. 24, Iss. 3, 2010-03 ,pp. : 245-262

Adis International

Access to resources Recommend Favorite

Agomelatine for the treatment of major depressive disorder

By Carney Regina M Shelton Richard C

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 15, 2011-10 ,pp. : 2411-2419

Informa Healthcare

Access to resources Recommend Favorite

Escitalopram: In the Treatment of Major Depressive Disorder in Adolescent Patients

By Yang Lily P.H. Scott Lesley J.

Pediatric Drugs, Vol. 12, Iss. 3, 2010-06 ,pp. : 155-163

Adis International

Access to resources Recommend Favorite

Selegiline Transdermal System: In the Treatment of Major Depressive Disorder

By Frampton James E. Plosker Greg L.

Drugs, Vol. 67, Iss. 2, 2007-01 ,pp. : 257-265

Adis International

Access to resources Recommend Favorite

Escitalopram for the treatment of major depressive disorder in youth

By Ahn Joon-Ho Patkar Ashwin A

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 14, 2011-10 ,pp. : 2235-2244

Informa Healthcare

Access to resources Recommend Favorite